Psychopharmacology and Experimental Therapeutics for Bipolar Depression

Differential diagnoses for bipolar depression include other mood disorders and personality disorder. More than half of patients with major depressive disorder endorse one or more subthreshold hypomanic symptoms, and the presence of these symptoms is associated with a lower likelihood of response to currently available treatments (6). Thus, a detailed history of prior symptomatic episodes and response to treatments may help in differentiating treatment-resistant major depressive disorder from bipolar depression. Among personality disorders, the affective instability and prominent mood symptoms associated with borderline personality disorder may often result in misdiagnosis of bipolar depression. Use of brief screening instruments for personality disorder, such as the Standardized Assessment of Personality—Abbreviated Scale (7), may aid clinicians in this regard. The presence of comorbid psychiatric disorders, including substance use disorder and cardiovascular and metabolic disorders (8, 9), may further limit the management of bipolar depression with currently available treatments. Thus, we recommend the use of structured or semistructured diagnostic instruments (such as the self-report Mood Disorders Questionnaire [10] or the clinician-administered Mini International Neuropsychiatric Interview [11]) to ascertain the diagnosis of bipolar depression and establish the presence of any comorbid psychiatric disorders (using a scale such as the Psychiatric Diagnostic Screening Questionnaire [12]). A detailed medical history, thorough physical, and routine lab work-up are also indicated to rule out medical conditions that may be mimicking or aggravating depressive symptoms, such as thyroid abnormalities, metabolic disorders, and obstructive sleep apnea (13, 14).

One of the three FDA-approved medications (olanzapine-fluoxetine combination, quetiapine, and lurasidone) should be considered as the first-line treatment for bipolar depression. Because no significant differences have been found in treatment outcomes among the first-step treatments (15), choice among these medications is often guided by the profile of anticipated side effects. Both olanzapine and quetiapine are associated with significant metabolic disturbance. However, their use may be preferred in patients with intractable insomnia because of their sedating side effects. Patients and their clinicians often must consider off-label use because of the limited efficacy of current FDA-approved treatments. For example, only 48.8% of patients receiving olanzapine attained remission during an eight-week-long acute-phase treatment (16). Similarly, remission rates with quetiapine and lurasidone ranged from 51.6% to 52.9% (17, 18) and 40% to 50% (19, 20) respectively.

We recommend the use of a measurement-based care approach, which includes assessments of symptoms (depressive and manic-hypomanic) and side effect severity along with adherence (21), so that patients and clinicians can systematically evaluate the efficacy and tolerability of FDA-approved treatments. Repeated laboratory, anthropometric, and electrocardiographic measurements are also needed to establish the long-term safety of the currently approved FDA treatments.

Aripiprazole, an atypical antipsychotic, was studied as a monotherapy for bipolar depression in two randomized controlled trials. No significant improvement was seen with aripiprazole, compared with placebo, during acute-phase treatment (22). A recent meta-analysis found that aripiprazole, along with ziprasidone (another atypical antipsychotic), was significantly less effective than lurasidone (15), suggesting that these medications should be avoided in patients with bipolar depression. Although asenapine has not been studied among patients with bipolar depression, it has been shown to be efficacious in reducing the severity of depression among people with mixed episodes (23). Among newer atypical antipsychotic medications, cariprazine at a dose of 1.5 mg/day, but not at doses of 0.75 mg/day and 3.0 mg/day, was found to be superior to placebo in reducing the severity of depression (24), warranting additional studies of this dose. In summary, the evidence for the efficacy of atypical antipsychotics is limited, except for those approved by the FDA for this indication (25).

Use of antidepressant medications remains common among patients with bipolar depression (26). A large study of treatment-seeking patients with bipolar depression, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial, compared the utility of adding antidepressant medication (paroxetine or bupropion) with placebo. This trial found no difference in rates of either symptomatic improvement or treatment-emergent affective switch among patients with bipolar depression (N=366) treated with antidepressant or placebo (27). In a study of patients with bipolar II disorder who were treated with sertraline alone, lithium alone, or a combination of sertraline and lithium, rates of treatment-emergent manic or hypomanic switch or rates of improvement did not differ among the three treatment arms over a 16-week double-blind period (28). Similarly, in a study of patients with bipolar depression who had attained remission with the addition of an antidepressant medication to ongoing mood stabilizer medication, discontinuation of antidepressant medication was associated with shorter time to relapse of depressive symptoms over a one-year follow-up period compared with continuation of an antidepressant over the same period (29). Taken together, these findings suggest that a subgroup of patients with bipolar depression may benefit from acute- or continuation-phase treatment with antidepressants.

Ketamine, which targets glutamatergic neurotransmission by inhibiting N-methyl-D-aspartate (NMDA) receptors, has been shown to be effective for patients with bipolar depression (30). In the first study of racemic ketamine (delivered via intravenous [IV] dosing) in bipolar depression, hospitalized patients (N=18) with bipolar depression who had not responded to at least one antidepressant treatment and were stable on a four-week course of mood stabilizer (lithium or sodium valproate) at a therapeutic level were randomized to a cross-over study with an infusion of either ketamine or saline, with repeat infusion with the alternate medication after two weeks (31). In this study, after a single IV infusion of ketamine, patients had a rapid reduction in both clinician-rated and self-reported severity of depression within 40 minutes after the end of infusion, and it was maintained for three days after infusion (31). The response rate among those who received ketamine (71%) was much higher than among those who received placebo (6%). These findings were replicated in a separate cohort of patients with bipolar depression (N=15). In this cohort, 79% of patients responded to ketamine, whereas 0% responded to placebo (32).

Since these initial publications, open-label studies of adults and adolescents with bipolar depression (33, 34) have reported on the therapeutic benefits of ketamine. In addition, ketamine has also been shown to rapidly reduce suicidal ideation among patients with bipolar depression (35). Reflecting these studies showing ketamine’s efficacy, practitioners in the community are already using it with patients with bipolar depression (36). The recently concluded phase-three studies of intranasal s-ketamine (also known as esketamine, one of two enantiomers [R,S] of the racimate) offer the potential for the availability to clinicians of an easy-to-administer ketamine formulation (37). Although double-blind studies have shown that the rate of manic or hypomanic switch did not differ between patients receiving ketamine and those receiving saline (31), caution regarding treatment-emergent affective switch is indicated in view of case reports after clinical ketamine infusion (38).

Riluzole has been studied among patients with bipolar depression. Two separate open-label studies showed a significant reduction in the severity of depression with riluzole in the 50- to 200-mg dose range (39, 40). However, a double-blind randomized placebo-controlled study with 94 patients with bipolar depression showed no significant improvement with 200 mg/day of riluzole over eight weeks compared with placebo (Payne et al., unpublished data, reported by http://www.stanleyresearch.org/03T-457). Lamotrigine, which modulates glutamate release and has been approved by the FDA for maintenance-phase treatment of bipolar disorder in preventing depressive relapse, was not more efficacious than placebo in four out of five studies of patients with bipolar depression (41). Memantine, an NMDA receptor antagonist, has also been studied among patients with bipolar depression. In two randomized controlled studies, memantine showed no significant reduction compared with placebo (42, 43). D-cycloserine, which binds to the glycine site of NMDA receptor, has been shown to prolong the antidepressant effect of ketamine (44).

A randomized controlled trial compared modafinil with placebo as an adjunctive treatment to mood stabilizer for six weeks (N=85) and found a significantly greater reduction in depression severity with modafinil (100–200 mg) than with placebo from baseline to week six (45). In addition, remission and response rates were significantly higher with modafinil, with no significant differences in treatment-emergent manic or hypomanic symptoms (45). Pramipexole, a dopamine agonist, was studied with a small group of patients (N=22) with bipolar depression (46). In this study, eight of 12 patients receiving pramipexole attained 50% or more reduction in symptoms (response) with six weeks of treatment (46). These findings were replicated with a separate group of patients with bipolar depression (47). Medications with no significant benefits over placebo in bipolar depression include ethyl-eicosapentanoic acid (48), mifepristone (49), levothyroxine 300 mcg/day (reported by Bauer et al.; http:/www.stanleyresearch.org/02T-238), ropinirole (reported by Grunhaus et al.; http://www.stanleyresearch.org/02T-123), levetiracetam (50), zonisamide (reported by Blumenthal et al.; http://www.stanleyresearch.org/07TGF-1163), tianeptine (reported by Kapczinski et al.; http://www.stanleyresearch.org/07TGF-1148), 4-aminopyridine (reported by Suppes et al.; http://www.stanleyresearch.org/04T-619), pregnenolone (reported by Brown et al.; http://www.stanleyresearch.org/09T-1280), and acetyl-l-carnitine plus alpha-lipoic acid (51).

Electroconvulsive therapy (ECT) remains the most effective treatment for treatment-refractory bipolar depression, with remission rates of 57%−63% (52). Repetitive transcranial magnetic stimulation (TMS), among other neurostimulation treatments, has been studied among patients with bipolar depression. Repetitive TMS using a figure-of-eight coil has not been shown to be effective with patients with bipolar depression (53). However, a recently reported small study of patients with bipolar depression reported that TMS using an H-coil (deep TMS) was more effective than sham (54). As reported in a recent review, TMS is well tolerated by patients with bipolar depression, but findings supporting its efficacy are limited (55). A small study showed that transcranial direct current stimulation (tDCS) resulted in a reduction in depressive symptoms among patients with bipolar depression that was similar in magnitude to that among patients with major depressive disorder (56). However, a larger study (N=120) of tDCS among patients with unipolar and bipolar depression showed that active tDCS was inferior to sham in reducing severity of depressive symptoms (Loo et al., unpublished study, http://www.stanleyresearch.org/11T-005). Similar outcomes were reported for deep brain stimulation of subcallosal cingulate among treatment-refractory patients with bipolar and unipolar depression (57).

Disruption of circadian rhythms among patients with bipolar disorder is well recognized and may play a pathophysiological role (58). Thus, bright light therapy has been proposed for treatment of patients with bipolar depression. A recent double-blind randomized placebo-controlled study of 46 patients with bipolar depression (59) found a significantly higher likelihood of remission with bright light therapy (68.2%) compared with control placebo red light (22.2%). In this study, patients started with 15-minute sessions of 7000-lux bright white light between 12:00 p.m. and 2:30 p.m., with the duration of light increased every week to the target dose of 60 minutes per daily session by week four. Patients were maintained on stable doses of their mood stabilizers throughout the study (59). Previous reports have shown the efficacy of light therapy combined with total sleep deprivation among patients with treatment-refractory bipolar depression (60). However, use of total sleep deprivation (61) and light therapy (62) with patients with bipolar disorder can provoke manic symptoms, restricting their use among patients with bipolar depression.

Lumateperone (also known as ITI-007) is an atypical antipsychotic that is an antagonist of the serotonin 2A receptor and a partial agonist of the presynaptic dopamine 2 receptor. It is currently in phase-three trials as monotherapy (ClinicalTrials.gov identifier NCT02600494) and as an adjunctive therapy to lithium and valproate (NCT02600507). Vortioxetine, an FDA-approved serotonin modulator antidepressant, is also being studied in a phase-two study (NCT03598868) as adjunctive treatment for bipolar depression. Another medication targeting monoamine neurotransmission is the compound JNJ-18038683, which is a 5-HT7 antagonist and is being evaluated for its effect on improving depression and cognitive symptoms among patients with bipolar disorder (NCT02466685).

An ongoing study is testing the efficacy of repeated infusions of ketamine with ECT in patients with treatment-refractory bipolar depression and major depressive disorder (NCT03674671). Strategies to prolong the antidepressant effect of ketamine infusion include a six-week course of D-cycloserine and lurasidone after a single infusion of ketamine (being developed as NRX-101; NCT03402152).

Minocycline has been shown to reduce depressive symptoms in open-label studies of bipolar depression (63). The combination of minocycline and aspirin was shown to have a rate of response 2.9 times higher than the placebo condition, but this difference was not statistically significant (64). Two ongoing studies are testing the efficacy of minocycline in combination with N-acetyl cysteine (NCT02719392) and celecoxib (NCT02703363), respectively. Because probiotics have been shown to reduce rehospitalization among patients with bipolar disorder after a manic episode (65), ongoing studies are testing their efficacy after patients have been hospitalized for bipolar depression (NCT03349528). Other anti-inflammatory treatments for bipolar depression currently being studied include fecal microbiota transplant (NCT03279224), celecoxib (NCT01479829, NCT02726659), and infliximab (NCT02363738).

Ongoing studies are also testing the efficacy of novel neurostimulation modalities. One of the most promising among modalities is magnetic seizure therapy (MST), which has been shown to have efficacy similar to ECT among patients with major depressive disorder, but without the cognitive side effects seen with ECT (66). A triple-blinded (participant, provider, and outcome assessor) randomized study plans to enroll 100 patients with treatment-refractory bipolar depression to test the efficacy and tolerability of MST versus ECT (NCT03641300). Low-frequency magnetic stimulation is another novel neurostimulation intervention for bipolar depression that is currently being studied (NCT02707276, NCT03484494). Of note, low-frequency magnetic stimulation was not superior to sham in a recently reported study of patients with treatment-resistant depression (67).

Other treatments currently being investigated for bipolar depression include bezafibrate (a lipid-lowering medication; NCT02481245), nitrous oxide (a noninflammable gas commonly used as an anesthetic drug in dental practices; NCT02757521), trehalose (a naturally occurring disaccharide that is commonly used as a food additive; NCT02800161), creatine monohydrate (an amino acid that is often used as a supplement; NCT01655030), and cannabidiol (a cannabis plant extract that has fewer psychoactive effects than tetrahydrocannabinol; NCT03310593). In addition, there is an ongoing study with patients with bipolar depression of a novel compound manufactured by Sunovion called SEP-4199 (NCT03543410).